Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Thiotepa for CNS Prophylaxis in High-risk DLBCL
NCT07493486Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Cumulative incidence of secondary central nervous system (SCNS) relapse at 2 years. Started Feb 2022; status: completed.
02
Drugs
thiotepa
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07493486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493486.